Phillipp Wolf

8PUBLICATIONS
76CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 31, 2025
Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.

Isis Wolf, Nora Giess, Céline Roider

|Jan 23, 2025
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer.

Isis Wolf, Susanne Schultze-Seemann, Christian Gratzke

|Jun 12, 2024
Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation.

Janaki Manoja Vinnakota, Rachael C Adams, Dimitrios Athanassopoulos

|May 27, 2024
Proteomic analysis of the urothelial cancer landscape.

Franz F Dressler, Falk Diedrichs, Deema Sabtan

|May 09, 2024
Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect.

Tamara Kögl, Hsin-Fang Chang, Julian Staniek

Pageof 2